2420 results about "Bioavailability" patented technology

The invention relates to the technical field of cosmetics, in particular to an acne-removing composition, lipidosome and a preparation method and application thereof. The acne-removing composition disclosed by the invention is prepared from the following components in parts by weight: 2 to 8 parts of nicotinamide, 1 to 5 parts of cortex magnoliae officinalis extract, 0.15 to 2.01 parts of glycyrrhizic acid, 0.1 to 2 parts of totarol and 0.01 to 0.15 part of hyssopus officinalis extract. The nano-carrier is adopted to wrap and deliver the acne removal composition, so that the solubility of the functional components is increased, the bioavailability of the functional components is improved, meanwhile, the irritation of the functional components is also improved, multi-target co-delivery and multi-mechanism acne removal are realized, and the acne removal composition has a remarkable acne removal effect.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The invention discloses a compound composition with a multi-target heart protection function as well as a preparation method and application of the compound composition. The composition is composed of a basic functional oil phase, a core antioxidant / anti-inflammatory phase, a myocardial nutrition and regulation phase and a bioavailability promotion phase in a synergistic manner, and is integrated into a composite cardiac oligopeptide and microencapsulated particle key component substance through a specific enzymolysis and microencapsulation embedding process system. The invention aims to solve the technical problems of single target spot, insufficient synergistic effect of all components, low bioavailability of active components and poor stability of the existing heart protection product, and provides a stable and easily-absorbed composite composition which can realize synergistic effect from multiple channels at the same time. Technical effect verification shows that under the condition of equal-dose sample feeding, the composition can remarkably improve the bioavailability of functional components and shows excellent myocardial cell oxidative damage resistance and myocardial ischemia improvement activity in cell and animal models, the effect is remarkably superior to that of independent use or simple physical mixing of all the components, and the composition is suitable for clinical application. And the substantial progress of synergistic interaction is proved. The composition can be used for developing various medicines, health foods and functional foods beneficial to heart health.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The invention provides tegorasan monoethyl fumarate as well as a preparation method, a pharmaceutical composition and an application of the tegorasan monoethyl fumarate. The tegorac monoethyl fumarate provided by the invention is relatively good in solubility and good in stability, the bioavailability of a medicine is increased by improving the solubility of the medicine, and the tegorac monoethyl fumarate is suitable for industrial production and has a good market prospect.

Stable and bioavailable formulations and dosage forms comprising a dispersion (e.g., spray-dried dispersion) of solid amorphous 6-(cyclopropancamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (Formula (I): BMS-986165) in a solid polymer matrix are provided for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis.

The invention discloses a preparation method of artemisia apiacea extracellular vesicles, which comprises the following steps: step 1, pre-treating artemisia apiacea, carrying out primary centrifugal treatment, removing large plant tissues and cell debris, carrying out secondary centrifugal treatment, filtering by a needle filter, and collecting; step 2, transferring the filtered suspension to a sucrose density gradient solution, then carrying out third centrifugal treatment, collecting the solution with the concentration of 30% in the layer, and carrying out fourth centrifugal treatment to obtain artemisia apiacea extracellular vesicles; the invention further discloses an artemisia apiacea extracellular vesicle, a pharmaceutical composition for treating cerebral apoplexy, a medicine and application of the artemisia apiacea extracellular vesicle in preparation of the medicine for treating cerebral apoplexy. The naturally-sourced vesicle delivery system provided by the invention is expected to have higher safety and lower toxic and side effects, and the enrichment concentration of the therapeutic component at the focus part of cerebral apoplexy is improved, so that the bioavailability and the treatment efficiency of the medicine are remarkably improved.

The invention relates to a composite hydroxypropyl methylcellulose skeleton sustained-release material and a preparation method thereof, and belongs to the technical field of drug sustained release. The sustained-release material is prepared from 70 to 90 parts of hydroxypropyl methylcellulose (HPMC), 10 to 20 parts of sodium alginate, 8 to 15 parts of chitosan, 0.1 to 0.2 part of Omega-3 fatty acid, 0.05 to 0.06 part of vitamin D, 2.5 to 5 parts of soluble calcium salt-zinc salt composite cross-linking agent, 0.5 to 1.5 parts of hydrolyzable cross-linking agent, 3 to 10 parts of enzyme sensitive auxiliary material, 1 to 5 parts of pore-foaming agent and 2 to 8 parts of hydrophobic blocking agent. The preparation method comprises the steps of raw material pretreatment and dry mixing, active component dispersion liquid preparation, wet granulation and primary cross-linking, secondary cross-linking and drying, vacuum drying and size stabilization, curing and packaging and the like. The sustained-release material provided by the invention has the advantages of controllable drug release rate, good mechanical strength and biodegradability, is suitable for sustained-release delivery of Omega-3 fatty acid, vitamin D and other active components, and can improve the bioavailability and stability of drugs.

The invention relates to the technical field of pharmaceutical preparations, and provides a minoxidil film coating agent as well as a preparation method and application thereof. The minoxidil film coating agent provided by the invention comprises 40-60% of propylene glycol, 3-7% of polyvinyl alcohol, 20-30% of ethanol, 1-7% of minoxidil and the balance of water. According to the invention, propylene glycol is taken as a solvent, a plasticizer and a transdermal absorption enhancer, polyvinyl alcohol is taken as a film-forming material, and ethanol is taken as a volatile agent, after administration, ethanol is volatilized to promote film formation of polyvinyl alcohol, and propylene glycol enhances the plasticity of the formed film, so that the effect of reducing liquid medicine loss is achieved, the local medicine concentration is increased, and the bioavailability is improved. The minoxidil liniment disclosed by the invention has excellent skin permeability, can effectively convey a medicine to a required part, and can ensure that the medicine is released at a fixed position of the skin and is accurately administered in a medicine release process, so that the stimulation of liquid medicine flow to other parts is reduced, and a good treatment effect is achieved.

The invention discloses a lipophilic liposome containing polydeoxyribonucleotide as well as a preparation method and application of the lipophilic liposome. The lipophilic liposome comprises the following components in parts by weight: 0.001-3 parts of polydeoxyribonucleotide; 0.5 to 3 parts of phospholipid; 0.1-2 parts of a cationic emulsifier; 0.1-3 parts of an anionic emulsifier; 40 to 70 parts of polyol; the total amount is 100 parts. According to the invention, an emulsifier system formed by combining lecithin with anionic and cationic compound surfactants is adopted, so that the transdermal absorption of PDRN is facilitated. The lipophilic liposome containing polydeoxyribonucleotide prepared by the invention can effectively resist nuclease degradation, prolong the acting time of PDRN in skin, and improve the skin anti-aging and repairing effects of the liposome. The anti-aging effect of the active ingredients is improved, and the bioavailability of the active ingredients is improved. The cosmetic composition can be widely applied to cosmetic formulas of various dosage forms.

The invention discloses radix ophiopogonis powder for relieving anxiety and improving sleep. The radix ophiopogonis powder is prepared by carrying out fermentation on radix ophiopogonis through plant lactobacillus GDMCC No. 64374 and carrying out enzymolysis treatment through pullulanase. The invention further discloses a preparation method and application of the radix ophiopogonis powder. The saponin content of the radix ophiopogonis powder is obviously increased. The radix ophiopogonis powder can be prepared into products in various forms, has the effects of relieving anxiety mood and improving sleep, is high in bioavailability and free of toxic and side effects, and can be eaten for a long time. Compared with the traditional radix ophiopogonis powder, the radix ophiopogonis powder disclosed by the invention is relatively low in safety risk and more obvious in effects of relieving anxiety mood and improving sleep.

Disclosed herein are dosage forms comprising a combination of: 1) an active pharmaceutical ingredient (API), 2) a cyclodextrin, and 3) a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the drug for the treatment of conditions such as pain.

The invention relates to the technical field of daily chemicals, and particularly discloses a scalp oil control composition for preventing alopecia seborrhoeica as well as a preparation method and application of the scalp oil control composition. The scalp oil control composition is prepared from the following main components: nicotinamide, capryloyl glycine, piralinone ethanolamine salt, betaine salicylic acid, lemon peel extract, white willow bark extract and rice fermentation filtrate. All the components have a synergistic effect, and the effects of controlling oil, protecting hair and preventing alopecia seborrhoeica are achieved. The preparation method disclosed by the invention is simple and convenient, and the obtained product is high in bioavailability of active ingredients, good in hair care effect and low in irritation, has the effects of caring hair, strengthening hair roots, regulating scalp micro-ecology and preventing seborrheic alopecia, and can be widely applied to related washing and care products for preventing seborrheic alopecia.

The invention relates to the field of biological medicine, in particular to a carrier-free nanoparticle which is formed by self-assembly of cyclosporine A and costunolide through intermolecular weak interaction. The invention also provides a preparation method of the traditional Chinese medicine composition and application of the traditional Chinese medicine composition in preparation of medicines for treating xerophthalmia. The carrier-free nano eye drops based on the synergistic effect of Chinese and western medicines are used for anti-inflammatory treatment of the xerophthalmia, a new strategy is provided for precise diagnosis and treatment of the xerophthalmia, the problems of single target spot, limited curative effect and the like in traditional treatment are solved, and more efficient inflammation control is expected to be achieved. While the curative effect is improved, the tolerance risk caused by long-term use is reduced, double optimization of the curative effect and safety is realized, and the limitation of traditional single drug treatment is broken through. By adopting the carrier-free nano preparation, the delivery efficiency of the medicine on the ocular surface is effectively improved, the bioavailability is enhanced, powerful support is provided for improving the curative effect of the medicine, and the carrier limitation bottleneck is broken through.

The invention discloses a composite curcumin nano pesticide and a preparation method and application thereof.The nano pesticide comprises a carrier and curcumin loaded on the carrier, the carrier is polydopamine-sodium lignin sulfonate, and the polydopamine-sodium lignin sulfonate is formed by polymerizing dopamine hydrochloride on the surface of lignin; the preparation method comprises the following steps: preparing a curcumin solution, adding the polydopamine-sodium lignin sulfonate powder, fully dispersing, slowly stirring under a dark condition until a yellow solution becomes dark red, and removing a solvent to obtain the polydopamine-sodium lignin sulfonate-curcumin. The nano pesticide provided by the invention takes polydopamine-sodium lignin sulfonate as a carrier, so that the drug has pH and photo-thermal response controlled release function, burst release of curcumin is avoided, and the stability and bioavailability of curcumin are improved.

The invention discloses a preparation method of deer spleen aminopeptide powder in the field of bioactive substance extraction and functional material compositing, and the performance of the deer spleen aminopeptide powder is improved by compositing a multi-stage functional modified material and deer spleen aminopeptide. The preparation method comprises the following steps: cleaning, homogenizing and crushing fresh deer spleen, extracting with a phosphate buffer solution, adjusting the pH value, carrying out enzymolysis, inactivating enzyme, and treating with an ultrafiltration membrane and a nanofiltration membrane in a specific molecular weight range to obtain a concentrated solution; and mixing the concentrated solution with a multi-stage functional modified material under proper conditions, sterilizing, pre-freezing, and freeze-drying to obtain the deer spleen aminopeptide powder. Wherein the modified material is constructed through quaternization modification, nanopore loading, enzyme inhibitor coupling and targeting ligand modification, and has the functions of charge repulsion, steric hindrance, enzyme inhibition and targeting recognition. The deer spleen aminopeptide powder prepared by the invention has high stability and good bioavailability, and is suitable for functional food or health care products.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a dammarane sapogenin-isatin derivative and application thereof in anti-tumor treatment. The dammarane sapogenin-isatin conjugate is constructed by taking dammarane sapogenin as a mother nucleus, deriving the dammarane sapogenin and chloroacetic acid and then introducing an indolone structural unit, and R1, R2 and R3 are as described in the claims and the specification. According to the invention, isatin fragments and ginsenoside are coupled for the first time, the anti-tumor activity of the compounds is systematically evaluated, and the action mechanism research of the compounds in colorectal cancer and other tumors is further developed. Results show that the obtained compound has relatively good anti-tumor efficacy, tumor cell selectivity, relatively low toxicity and relatively high bioavailability, and shows good patent medicine potential and wide market prospects.

The invention relates to the technical field of biological agents, and discloses a passivating enzyme soluble concentrate and a preparation process thereof.The soluble concentrate takes a specially-designed multifunctional deep eutectic solvent as a unique carrier, and the solvent has the multiple functions of stabilizing enzyme conformation, resisting oxidation, providing plant metabolism and increasing energy and the like. An active component is composite passivating enzyme powder which is subjected to vacuum freeze drying, and is compounded with a plant-derived phloem conduction enhancer in a synergetic manner. The preparation process adopts a core strategy of curing first and then dissolving, and the enzyme freeze-dried powder is dispersed in the non-aqueous solvent under low-temperature mild conditions. By constructing a water-free environment and adopting an activity protection process, the problems that a traditional water-based enzyme preparation is unstable in storage and the activity is easy to lose are fundamentally solved, and meanwhile, the bioavailability is remarkably improved by virtue of a targeted conduction component. The preparation has the remarkable advantages of ultra-long stability at normal temperature, high initial enzyme activity and strong targeting property.

The invention discloses a nanometer fiber yarn-based phytosterol Pickering emulsion as well as a preparation method and application thereof, and the nanometer fiber yarn-based phytosterol Pickering emulsion comprises the following components in parts by weight: 0.5-1 part of nanometer fiber yarn; 1 to 10 parts of phytosterol / phytosterol ester; 95 to 105 parts of a water phase component; 95 to 105 parts of an oil phase component; the nanofibers are extracted from agricultural wastes; according to the invention, the nanofiber is used as the only or main stabilizer of the phytosterol Pickering emulsion, so that the problems of solubility, emulsion stability and bioaccessibility of phytosterol can be solved at the same time; and efficient interface stability and steric hindrance stability are realized by utilizing a unique nano network structure of the nano fiber yarns, and a natural, safe and efficient phytosterol delivery system is provided.

Described herein are stable formulations of a peptide derived from Chaperonin 60.1 suitable for subcutaneous administration. The formulation may have Chaperonin 60.1-related peptide with a concentration of concentration of 16‑150 mg / mL capable of delivering a dose of at least 40 mg in an injection volume of 2 mL or less, and a bioavailability of at least 50%.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The invention belongs to the technical field of medicines, and particularly provides a solid dispersion as well as a preparation method and application thereof. The solid dispersion comprises a carrier material, and further comprises quercetagetin and phospholipid, the mass ratio of the quercetagetin to the phospholipid is 1: (0.3-1.5), and the carrier material comprises one or more of a hydrophilic polymer and a pH-dependent polymer. Wherein the quercetagetin and the phospholipid are combined through an intermolecular force, so that the quercetagetin obtains a lipid material similar to a cell membrane structure, a cell membrane bionic phospholipid compound is formed, the cell membrane bionic phospholipid compound can be naturally compatible with an upper wall cell membrane of a small intestine, and the permeation transmembrane capability of the quercetagetin is better promoted; the quercetagetin is added into the solid dispersion, so that more quercetagetin can enter systemic circulation and lymphatic circulation, and therefore, the solid dispersion can strengthen transmembrane absorption while strengthening dissolution, so that the solid dispersion has high bioavailability.

The invention provides a compound for improving mitochondrial functions and preventing and treating senescence and mitochondrial related diseases as well as a preparation method and application of the compound, and belongs to the technical field of medicinal chemistry. The invention provides a compound for improving mitochondrial function and preventing and treating senescence and mitochondrial related diseases or a pharmaceutically acceptable salt thereof. The compound has a structure as shown in a formula 1; the compound provided by the invention is good in solubility and high in bioavailability, and can be used for preventing and / or treating diseases related to mitochondrial functions.

The invention discloses a sustained-release pill as well as a preparation method and application thereof, and belongs to the technical field of medicines. The sustained-release pill comprises a pill core and a coating layer coated outside the pill core, the pellet core is prepared from the following raw materials in parts by mass: 8 to 14 parts of loxoprofen sodium, 30 to 60 parts of a filling agent, 3 to 10 parts of an adhesive, 2 to 10 parts of a disintegrating agent, 0.1 to 2 parts of a penetration enhancer, 0.05 to 0.2 part of a pH regulator, 0.1 to 0.5 part of a surfactant and 0 to 20 parts of an auxiliary agent; the coating layer is prepared from an aqueous dispersion liquid containing acrylic resin; the coating layer is prepared from an aqueous dispersion liquid containing acrylic resin. Aiming at the drug characteristics of loxoprofen sodium, the loxoprofen sodium sustained-release tablet is composed of specific auxiliary materials, the drug composition is optimized, the drug release rate is accurately controlled, the bioavailability and stability of the drug are effectively improved, and the loxoprofen sodium sustained-release tablet has a good application prospect in preparation of antipyretic and analgesic drugs.

The invention discloses extraction of polydeoxyribonucleotide as well as preparation and application of a PDRN-Ce (Polydeoxyribonucleotide-Ce) microsphere cluster. The extraction and purification method comprises the following steps: mixing in-vitro fish testis tissues with water, carrying out crushing treatment and homogenization treatment on an obtained premix, carrying out proteolysis and solid-liquid separation, and collecting supernate to obtain enzymatic hydrolysate; wherein protease used for proteolysis comprises neutral protease; carrying out alcohol precipitation on the enzymatic hydrolysate by adopting an alcohol solvent, and collecting a precipitate; and dissolving the precipitate in water, desalting and drying. According to the extraction method, the purity and the yield of the poly-deoxyribonucleotide are remarkably improved, the preparation method is low in cost and convenient to operate, the prepared poly-deoxyribonucleotide is stable in property, small in molecular weight and easy to absorb by skin, in order to further improve the bioavailability of the extracted poly-deoxyribonucleotide, the PDRN-Ce microsphere cluster is prepared, and the PDRN-Ce microsphere cluster can be used for preparing the poly-deoxyribonucleotide. Good application prospects are realized.